Curanex Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	-	-	-	0.03
Cost of Revenue	-	-	-	0.02
Gross Profit	-	-	-	0
Selling, General & Admin	0.36	0.29	0.02	0.02
Operating Expenses	0.36	0.29	0.02	0.02
Operating Income	-0.36	-0.29	-0.02	-0.02
Other Non Operating Income (Expenses)	0.01	0	0	-
EBT Excluding Unusual Items	-0.36	-0.29	-0.02	-0.02
Asset Writedown	-0.07	-0.07	-	-
Pretax Income	-0.44	-0.36	-0.02	-0.02
Net Income	-0.44	-0.36	-0.02	-0.02
Net Income to Common	-0.44	-0.36	-0.02	-0.02
Shares Outstanding (Basic)	24	13	1	1
Shares Outstanding (Diluted)	24	13	1	1
Shares Change (YoY)	1503.93%	2109.84%	-	-
EPS (Basic)	-0.02	-0.03	-0.03	-0.03
EPS (Diluted)	-0.02	-0.03	-0.03	-0.03
Gross Margin	-	-	-	17.04%
Operating Margin	-	-	-	-77.82%
Profit Margin	-	-	-	-77.82%
EBIT	-0.36	-0.29	-0.02	-0.02
EBIT Margin	-	-	-	-77.82%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q